Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Hangping Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6742-7074; OpenAlex author ID A5081214301, A5103742527. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 13

  1. Antibody-drug conjugates specifically regulate tumor microenvironment: A promising strategy for pancreatic cancer treatment. Last author DOI 10.1016/j.hbpd.2025.12.010↗
  2. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy. Co-author DOI 10.1016/j.bbcan.2020.188360↗
  3. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pa… Last author DOI 10.3389/fonc.2019.01377↗
  4. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Co-author DOI 10.1021/acs.molpharmaceut.8b00298↗
  5. HINT2 triggers mitochondrial Ca2+ influx by regulating the mitochondrial Ca2+ uniporter (MCU) complex and enhances gemcitabine apoptotic effect in pancreatic c… Co-author DOI 10.1016/j.canlet.2017.09.020↗
  6. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer. Last author DOI 10.1016/j.humpath.2017.05.023↗
  7. MicroRNA Expression Profiling of Pancreatic Cancer Cell Line L3.6p1 Following B7-H4 Knockdown. Last author DOI 10.1159/000485086↗
  8. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases. Last author DOI 10.18632/oncotarget.12665↗
  9. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Co-author PMID 27293990↗
  10. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Co-author DOI 10.1158/1535-7163.mct-13-0242↗
  11. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Co-author DOI 10.1007/s00441-013-1640-8↗
  12. [Preparation of anti-B7-H4 monoclonal antibody to investigate B7-H4 expression in pancreatic cancer]. Last author PMID 24167131↗
  13. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutic… Co-author DOI 10.1021/mp200193u↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ming‐Hai Wang · 6 shared papers, 2011–2020 · strength 0.51
  2. Bo Hong · 6 shared papers, 2013–2019 · strength 0.38
  3. Jiale Zhang · 1 shared paper, 2026 · strength 0.36
  4. Yun Qian · 4 shared papers, 2016–2019 · strength 0.27
  5. Chenyu W Hu · 3 shared papers, 2017–2019 · strength 0.24
  6. Linghui Chen · 2 shared papers, 2017–2018 · strength 0.14
  7. Weilin Wang · 2 shared papers, 2017–2018 · strength 0.14
  8. Lingwei Shen · 2 shared papers, 2017 · strength 0.13
  9. Wenxuan Wu · 2 shared papers, 2017 · strength 0.13
  10. Ruiwen Zhang · 2 shared papers, 2011–2016 · strength 0.11
  11. Xiangming Xu · 1 shared paper, 2019 · strength 0.09
  12. Qi Wang · 1 shared paper, 2017 · strength 0.06
  13. Dongkai Zhou · 1 shared paper, 2017 · strength 0.06
  14. Shusen Zheng · 1 shared paper, 2017 · strength 0.06
  15. Wei Song · 1 shared paper, 2017 · strength 0.06
  16. Jun-Ying Zeng · 1 shared paper, 2014 · strength 0.05
  17. Lihuang Zhang · 1 shared paper, 2013 · strength 0.04
  18. Yun Qian · 1 shared paper, 2013 · strength 0.04
  19. Snehal Padhye · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.